Abstract:Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: In patients with refractory or relapsed (R/R) B-cell lymphoma, the persistence of positive laboratory tests (polymerase chain reaction, PCR) was significantly prolonged and the timing of cancer treatment was significantly affected. There have been few clinical trials of cancer treatment in the setting of persistently positive PCR in R/R B-cell lymphoma. Aims: The purpose of this study was to evaluate the outcomes of COVID-19 and the prognosis of lymphoma in patients with R/R B-cell lymphoma after cancer treatments performed during the positive molecular phase of COVID-19. Methods: From December 2022 to February 2023, 40 patients with COVID-19 infection were enrolled. Median age was 33 (25-81) years. Diagnoses included DLBCL(NOS)(n=23), MCL(n=2),TFL(n=3), BL (n=3),and Other(n=9). 36/40 (90%) patients were at stage III-IV at the time of salvage therapy. The median IPI score was 2 (range 1-5). All patients were those with progressive disease who had failed multi-line therapy, including CD19 CAR -T therapy (n=30). Patients were heavily pretreated with a median of 6 (range 2-13) cycles of therapy. in 17/25 patients with COVID-19, therapy with CAR -T cells lasted less than 3 months, and in 6/25 of them less than 1 month.COVID-19 treatments included nirmatrelvir/ritonavir, azvudine, human immunoglobulin (PH4). Treatments with glucocorticoids and/or targeted interleukin-6 had severe COVID-19. To further reduce tumor burden, anti-cancer drugs were approved for patients with rapid tumor progression with COVID-19. Results: Weakness, cough, and fever occurred in 32/40 (80%), 22/40 (55%), and 23/40 (57.5%) of patients, respectively, and 10/40 (25%) had severe COVID-19. The median duration of persistent positive PCR was 32 days (4-58), with a median follow-up of 49 days (28-70).During follow-up, 14/40 (35%) patients had persistent positive PCR even after receiving COVID-19 treatment, and the number of those who had severe COVID-19 pneumonia was higher than those who had negative PCR (8/14, 57.1% vs2/26, 7.69%, p=0.0012).We found no increase in severe COVID-19 pneumonia and grade III-IV CRS in patients with positive molecules treated with CART within three months. Patients with COVID-19 showed decreased numbers of all T-cell subsets. The median CD4/CD8 ratio was 0.59 (range 0.12-1.65).Anti-cancer treatments were approved for 37/40 (92.5%) patients with rapid tumor progression to COVID -19, of whom 14/37 (37.8%) were treated with CAR -T and 23/37 (62.1%) received chemotherapy. The number of patients with persistently positive PCR was 13/37 (35.1%) in the treated cohort compared with 1/3 (33.3%) in the untreated cohort (P=0.337). 6/14 (42.8%) in the CART cohort and 7/23 (30.4%) in the chemotherapy cohort of patients with persistent positive PCR (P=0.49). There were 7/37 (18.9%) cases of severe COVID-19 in the treated cohort and 3/3 (100%) cases in the untreated cohort. After cancer treatment, 15/30 (50%) of evaluable patients had controlled progression of lymphoma. 3 patients (3/40, 7.5%) died of disease progression and 3 patients (3/40, 7.5%) died of severe and fatal COVID -19. Summary/Conclusion: Both tumor progression and COVID-19 may affect survival of patients with progressive R/R B-cell lymphoma, and anti-cancer drugs should be approved for R/R B-cell lymphoma patients with positive PCR. Keywords: Non-Hodgkin’s lymphoma, CAR-T, PCR, COVID-19

Impact of chemotherapy on lymphocytes and serological memory in recovered COVID-19 patients with acute leukemia

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

Assessing the impact of COVID-19 on acute leukemia patients: a comparative analysis of hematological and biochemical parameters

Impact of Chemotherapy and Immunotherapy on the Composition and Function of Immune Cells in COVID-19 Convalescent with Gynecological Tumors.

Restoration of Leukomonocyte Counts is Associated with Viral Clearance in COVID-19 Hospitalized Patients

Low Humoral Immune Response and Ineffective Clearance of SARS-Cov-2 in a COVID-19 Patient with CLL During a 69-Day Follow-Up.

The impact of recent chemotherapy on immunity in 2 COVID-19 cases with gastrointestinal tumors: A case report

PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA

COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study

COVID-19 in patients receiving treatment at an outpatient chemotherapy unit

Impact of Chemotherapy on Circulating Lymphocyte Subsets in Lung Cancer Patients

Impact of SARS-CoV-2 infection on patients with hematological malignancies: a retrospective study

Changes of immune pattern in lung cancer patients before and after chemotherapy

SARS-CoV-2 and chronic myeloid leukemia: a systematic review

How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy

COVID-19 in Persons with Chronic Myeloid Leukaemia

Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19

Diagnosing B-cell acute lymphoblastic leukemia in 2 pediatric patients with recent SARS-CoV-2 infection

Post-Chemotherapy Clinical Perianal Infection Features in Patients with Acute Leukemia

Exploring risk factors and molecular targets in leukemia patients with COVID-19: a bioinformatics analysis of differential gene expression

Hematologic changes predict clinical outcome in recovered patients with COVID-19